1. Home
  2. ENTX vs NBRG Comparison

ENTX vs NBRG Comparison

Compare ENTX & NBRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ENTX

Entera Bio Ltd.

HOLD

Current Price

$1.18

Market Cap

62.6M

Sector

Health Care

ML Signal

HOLD

NBRG

Newbridge Acquisition Limited Class A Ordinary Share

N/A

Current Price

$9.90

Market Cap

74.5M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
ENTX
NBRG
Founded
2010
2021
Country
Israel
Hong Kong
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
62.6M
74.5M
IPO Year
2015
2026

Fundamental Metrics

Financial Performance
Metric
ENTX
NBRG
Price
$1.18
$9.90
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$9.00
N/A
AVG Volume (30 Days)
135.1K
39.5K
Earning Date
05-14-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.25
N/A
Revenue
$42,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$4.48
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$9.59
52 Week High
$3.22
$9.91

Technical Indicators

Market Signals
Indicator
ENTX
NBRG
Relative Strength Index (RSI) 49.10 62.50
Support Level $1.17 N/A
Resistance Level $1.38 N/A
Average True Range (ATR) 0.10 0.03
MACD 0.00 0.00
Stochastic Oscillator 30.77 96.87

Price Performance

Historical Comparison
ENTX
NBRG

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

About NBRG Newbridge Acquisition Limited Class A Ordinary Share

Newbridge Acquisition Ltd is a blank check company.

Share on Social Networks: